Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure
L‐s Camilla d'Angelo, George Savulich, Barbara J. Sahakian
British Journal of Pharmacology April 20, 2017 DOI: 10.1111/bph.13813 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Citations | 95 |
| Key points | Argues that cognitive enhancers offer substantial potential benefits for neurodegenerative and psychiatric disorders and merit continued development, while their growing non-medical use by healthy individuals raises safety, ethical and regulatory concerns. The authors also contend that better understanding of the consequences, motivations and profiles of novel psychoactive substance users could support more effective prevention and harm reduction. |
Abstract
Today, there is continued, and in some cases growing, availability of not only psychoactive substances, including treatments for mental health disorders such as cognitive enhancers, which can enhance or restore brain function, but also 'recreational' drugs such as novel psychoactive substances (NPS). The use of psychoactive drugs has both benefits and risks: whilst new drugs to treat cognitive symptoms in neuropsychiatric or neurodegenerative disorders could have great benefits for many patient groups, the increasing ease of accessibility to recreational NPS and the increasing lifestyle use of cognitive enhancers by healthy people means that the effective management of psychoactive substances will be an issue of increasing importance. Clearly, the potential benefits of cognitive enhancers are large and increasingly relevant, particularly as the population ages, and for this reason, we should continue to devote resources to the development of cognitive enhancers as treatments for neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease, attention deficit hyperactivity disorder and schizophrenia. However, the increasing use of cognitive enhancers by healthy individuals raises safety, ethical and regulatory concerns, which should not be ignored. Similarly, understanding the short- and long-term consequences of the use of NPS, as well as better understanding the motivations and profiles of users could promote more effective prevention and harm reduction measures. Linked Articles This article is part of a themed section on Pharmacology of Cognition: a Panacea for Neuropsychiatric Disease? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.19/issuetoc.
Citations in the library
Cited by 5
- Ethical principles of traditional Indigenous medicine to guide western psychedelic research and practice. Lancet Regional Health. Americas February 1, 2023
- Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives Transcultural Psychiatry August 29, 2022
- The rising use of cognitive enhancement drugs and predictors of use during COVID-19: findings from a cross-sectional survey of students and university staff in the UK. Frontiers in Psychology 2024
- LSD et MDMA en combinaison (Candy Flip) Psychotropes April 21, 2023
- "Hot" and "Cold" Cognition in Users of Club Drugs/Novel Psychoactive Substances. Frontiers in Psychiatry March 24, 2021
Cites 11
- Beyond THC: The New Generation of Cannabinoid Designer Drugs Frontiers in Behavioral Neuroscience 2011
- Novel psychoactive substances of interest for psychiatry World Psychiatry February 1, 2016
- Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants Frontiers in Neuroscience April 19, 2016
- “Spiceophrenia”: a systematic overview of “Spice”‐related psychopathological issues and a case report Human Psychopharmacology: Clinical and Experimental July 1, 2013
- The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations International Journal of Drug Policy March 23, 2016
and 6 more in the library